Yehui Pharmaceutical Technology

Yehui Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. Founded in 2018 by Dr. Hua Mu, the company leverages deep expertise in drug discovery and clinical development to target high-potential biological pathways. Its lead candidate, YH-291, is a highly selective TYK2 inhibitor currently in Phase 2 clinical trials for the treatment of psoriasis. Additionally, the company is advancing YH-312, an HPK1 inhibitor, into clinical studies for solid tumors. Yehui is supported by a consortium of leading life science investors, including 6 Dimensions Capital and Boyu Capital, to accelerate its mission of providing transformative medicines to patients globally.